Abstract: An overlay network is enhanced to provide traffic delivery using anycast and end user mapping. An anycast IP address is associated with sets of forwarding machines positioned in the overlay network. These locations correspond with IP addresses for zero rated billing traffic. In response to receipt at a forwarding machine of a packet, the machine issues an end user mapping request to the mapping mechanism. The mapping request has an IP address associated with the client from which the end user request originates. The mapping mechanism resolves the request and provides a response to the request. The response is an IP address associated with a set of server machines distinct from the forwarding machine. The forwarding machine encapsulates the packet and proxies the connection to the identified server. The server receives the connection, decapsulates the request, and processes the packet. The server machine responds to the requesting client directly.

Abstract: An overlay network is enhanced to provide traffic delivery using anycast and end user mapping. An anycast IP address is associated with sets of forwarding machines positioned in the overlay network. These locations correspond with IP addresses for zero rated billing traffic. In response to receipt at a forwarding machine of a packet, the machine issues an end user mapping request to the mapping mechanism. The mapping request has an IP address associated with the client from which the end user request originates. The mapping mechanism resolves the request and provides a response to the request. The response is an IP address associated with a set of server machines distinct from the forwarding machine. The forwarding machine encapsulates the packet and proxies the connection to the identified server. The server receives the connection, decapsulates the request, and processes the packet. The server machine responds to the requesting client directly.

Abstract: An overlay network is enhanced to provide traffic delivery using anycast and end user mapping. An anycast IP address is associated with sets of forwarding machines positioned in the overlay network. These locations correspond with IP addresses for zero rated billing traffic. In response to receipt at a forwarding machine of a packet, the machine issues an end user mapping request to the mapping mechanism. The mapping request has an IP address associated with the client from which the end user request originates. The mapping mechanism resolves the request and provides a response to the request. The response is an IP address associated with a set of server machines distinct from the forwarding machine. The forwarding machine encapsulates the packet and proxies the connection to the identified server. The server receives the connection, decapsulates the request, and processes the packet. The server machine responds to the requesting client directly.

Abstract: An overlay network is enhanced to provide traffic delivery using anycast and end user mapping. An anycast IP address is associated with sets of forwarding machines positioned in the overlay network. These locations correspond with IP addresses for zero rated billing traffic. In response to receipt at a forwarding machine of a packet, the machine issues an end user mapping request to the mapping mechanism. The mapping request has an IP address associated with the client from which the end user request originates. The mapping mechanism resolves the request and provides a response to the request. The response is an IP address associated with a set of server machines distinct from the forwarding machine. The forwarding machine encapsulates the packet and proxies the connection to the identified server. The server receives the connection, decapsulates the request, and processes the packet. The server machine responds to the requesting client directly.

Abstract: An overlay network is enhanced to provide traffic delivery using anycast and end user mapping. An anycast IP address is associated with sets of forwarding machines positioned in the overlay network. These locations correspond with IP addresses for zero rated billing traffic. In response to receipt at a forwarding machine of a packet, the machine issues an end user mapping request to the mapping mechanism. The mapping request has an IP address associated with the client from which the end user request originates. The mapping mechanism resolves the request and provides a response to the request. The response is an IP address associated with a set of server machines distinct from the forwarding machine. The forwarding machine encapsulates the packet and proxies the connection to the identified server. The server receives the connection, decapsulates the request, and processes the packet. The server machine responds to the requesting client directly.

Abstract: A system and methods for generating 3D images from 2D bioluminescent images and visualizing tumor locations are provided. A plurality of 2D bioluminescent images of a subject are acquired using any suitable bioluminescent imaging system. The 2D images are registered to align each image and to compensate for differences between adjacent images. After registration, corresponding features are identified between consecutive sets of 2D images. For each corresponding feature identified in each set of 2D images, an orthographic projection model is applied, such that rays are projected through each point in the feature. The intersection points of the rays are plotted in a 3D image space. All of the 2D images are processed in the same manner, such that a resulting 3D image of a tumor is generated.

Abstract: An overlay network is enhanced to provide traffic delivery using anycast and end user mapping. An anycast IP address is associated with sets of forwarding machines positioned in the overlay network. These locations correspond with IP addresses for zero rated billing traffic. In response to receipt at a forwarding machine of a packet, the machine issues an end user mapping request to the mapping mechanism. The mapping request has an IP address associated with the client from which the end user request originates. The mapping mechanism resolves the request and provides a response to the request. The response is an IP address associated with a set of server machines distinct from the forwarding machine. The forwarding machine encapsulates the packet and proxies the connection to the identified server. The server receives the connection, decapsulates the request, and processes the packet. The server machine responds to the requesting client directly.

Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.

Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.

Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.

Abstract: A system and methods for generating 3D images from 2D bioluminescent images and visualizing tumor locations are provided. A plurality of 2D bioluminescent images of a subject are acquired using any suitable bioluminescent imaging system. The 2D images are registered to align each image and to compensate for differences between adjacent images. After registration, corresponding features are identified between consecutive sets of 2D images. For each corresponding feature identified in each set of 2D images, an orthographic projection model is applied, such that rays are projected through each point in the feature. The intersection points of the rays are plotted in a 3D image space. All of the 2D images are processed in the same manner, such that a resulting 3D image of a tumor is generated.

Abstract: Extracellular matrix bioscaffolds capable of supporting the formation and growth of tumors from tumor cells introduced thereto containing tumor associated macrophages and carcinoma-associated fibroblast-like cells cultured under conditions effective to provide a cellular matrix capable of supporting the formation and growth of tumors from tumor cells introduced to the matrix. Bioscaffold kits and methods for using the bioscaffolds for testing, identifying and development of known or novel anti-cancer therapeutics are also disclosed.

Abstract: A system and methods for generating 3D images (24) from 2D bioluminescent images (22) and visualizing tumor locations are provided. A plurality of 2D bioluminescent images of a subject are acquired during a complete revolution of an imaging system about a subject, using any suitable bioluminescent imaging system. After imaging, the 2D images are registered (20) according to the rotation axis to align each image and to compensate for differences between adjacent images. After registration (20), corresponding features are identified between consecutive sets of 2D image (22). For each corresponding feature identified in each set of 2D images an orthographic projection model (24) is applied, such that rays are projected through each point in the feature. The intersection point of the rays are plotted in a 3D image of a tumor is generated. The 3D image can be registered with a reference image of the subject, so that the shape and location of the tumor can be precisely visualized with respect to the subject.

Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.

Abstract: The present invention relates to combinations of Aplidine with Gemcitabine, and the use of these combinations in the treatment of cancer.

Abstract: Methods for the treatment of disorders, including cancer, are described which include administering to a subject a DNA methylation inhibitor and an antineoplastic agent. Compositions containing a DNA methylation inhibitor and an antineoplastic agent, which are useful in treating disorders including cancer, are also described. Additionally, methods useful for developing a prognosis for or diagnosing a subject's development of resistance to treatment with a chemotherapeutic agent are described.

Abstract: A system and methods for generating 3D images (24) from 2D bioluminescent images (22) and visualizing tumor locations are provided. A plurality of 2D bioluminescent images of a subject are acquired during a complete revolution of an imaging system about a subject, using any suitable bioluminescent imaging system. After imaging, the 2D images are registered (20) according to the rotation axis to align each image and to compensate for differences between adjacent images. After registration (20), corresponding features are identified between consecutive sets of 2D image (22). For each corresponding feature identified in each set of 2D images an orthographic projection model (24) is applied, such that rays are projected through each point in the feature. The intersection point of the rays are plotted in a 3D image of a tumor is generated. The 3D image can be registered with a reference image of the subject, so that the shape and location of the tumor can be precisely visualized with respect to the subject.

Abstract: A method is provided for use in producing a selected protein in mammalian cells, and to cDNA molecules useful in the method, and fusion proteins produced from expression of the cDNA. In the method, cDNA encoding a fusion protein that includes a mammalian DHFR and the selected protein is introduced into mammalian cells such that it is expressed. The naturally occurring repression of DHFR translation is overcome by treatment of the cells with a folate or antifolate or similar composition. The relief from this repression extends to the selected protein which is the second part of the expressed fusion, such that the treatment results in controllable and enhanced production of the selected protein.

Abstract: New mutant forms of human dihydrofolate reductase (DHFR) which have properties superior to the previously disclosed mutants have mutations at both amino acid 22 and amino acid 31. Specific mutant forms are Ser31Tyr22, Ser31Phe22, Gly31Tyr22, Gly31Phe22, Ala31Tyr22 and Ala31Phe22. The mutant DHFR of the invention may be used as a selectable marker, and to modify the genome of human cells, particularly bone marrow cells or peripheral blood stem cells, to render them resistant to chemotherapy using antifolate agents.

Abstract: A method is provided for use in producing a selected protein in mammalian cells, and to cDNA molecules useful in the method, and fusion proteins produced from expression of the cDNA. In the method, cDNA encoding a fusion protein that includes a mammalian DHFR and the selected protein is introduced into mammalian cells such that it is expressed. The naturally occurring repression of DHFR translation is overcome by treatment of the cells with a folate or antifolate or similar composition. The relief from this repression extends to the selected protein which is the second part of the expressed fusion, such that the treatment results in controllable and enhanced production of the selected protein.